Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis
Date:
17/10/2013
Location:
European Medicines Agency, London, UK
The main goal of the workshop is to make sure that in the revision of the multiple-sclerosis guideline, the European Medicines Agency can take the most up-to-date, state-of-the-art scientific developments in multiple sclerosis into consideration, as well as the positions of experts in the field on the main topics in the guideline.
-
List item
Agenda - Programme - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis (PDF/237.23 KB)
First published: 07/10/2013
Last updated: 07/10/2013
EMA/263897/2013 -
List item
Summaries of the presentations - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis (PDF/134.22 KB)
First published: 07/10/2013
Last updated: 07/10/2013
EMA/576938/2013 -
List item
Invitation for expressions of interest - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis (PDF/82.06 KB)
First published: 20/06/2013
Last updated: 20/06/2013
EMA/346872/2013 -
List item
Presentation - Disability assessment: can we combine responsiveness and clinical relevance? (Bernard Uitdehaag) (PDF/528.89 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Cognition and fatigue as major determinants of disability (Bernd C. Kieseier) (PDF/859.82 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Optical coherence tomography: A role in monitoring multiple sclerosis (Celia Oreja-Guevara) (PDF/2.31 MB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - New perception of disability – including cognition, fatigue, pain and other impairments related to multiple sclerosis (Diego Cadavid) (PDF/463.39 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Patient-reported outcomes, biomarkers and novel methodologies, and their role in the development of new multiple sclerosis medicines (Frank Dahlke) (PDF/274.2 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - The staggered two-step approach for treatments with profound effect on immunity (Gavin Giovannoni) (PDF/2.41 MB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Critical review of outcomes used in MS clinical trials (George Ebers) (PDF/402.38 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - The new outcome measures in MS: possible better ways to assess disability that overcome the limitations of the EDSS (Gilmore O'Neill) (PDF/666.52 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Changes in Patient Population - Insufficient Treatment Response (Gordon Francis) (PDF/406 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - The proposed ‘two-step approach’ for MS treatments with a significant effect on immunity (Hideki Garren) (PDF/401.64 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Multi-arm trials with repurposed drugs in progressive MS (Jeremy Chataway) (PDF/2.08 MB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Approaches to advancing patient focussed outcomes assessment in clinical trials (Jeremy Hobart) (PDF/1.92 MB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Treatment guidelines for relapsing MS and the ‘two step approach’ for disease modifying therapy (Klaus Schmierer) (PDF/4.3 MB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible (Luca Massacesi) (PDF/435.26 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Design strategies to minimise the use of placebo in MS clinical trials (Maria Pia Sormani) (PDF/781.99 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Assessing benefit/risk profile of novel immunomodulatory drugs with significant efficacy but potential risks. What data should be presented at MAA? (Michael Panzara) (PDF/949.62 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Issues regarding use of placebo in multiple sclerosis drug trials (Peter Scott Chin) (PDF/307.57 KB)
First published: 12/11/2013
Last updated: 12/11/2013 -
List item
Presentation - Clinical development issues in progressive multiple sclerosis(Volker Knappertz) (PDF/2.06 MB)
First published: 12/11/2013
Last updated: 12/11/2013